Next Article in Journal
Ivabradine Prevents Heart Rate Acceleration in Patients with Chronic Obstructive Pulmonary Disease and Coronary Heart Disease after Salbutamol Inhalation
Next Article in Special Issue
Newer Anticoagulants for Non-Valvular Atrial Fibrillation
Previous Article in Journal
Epigenetic Mechanisms and Therapeutic Perspectives for Neurodevelopmental Disorders
Previous Article in Special Issue
Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
Pharmaceuticals 2012, 5(4), 384-397; doi:10.3390/ph5040384

Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines

1, 2, 3 and 4,*
1 Cardiac Arrhythmias and Electrophysiology, Dante Pazzanese Institute of Cardiology, Sao Paulo 04012-180, Brazil 2 1506 Bristol Court, Elizabethtown, KY 42701, USA 3 Department of Medicine, Cardiology Division, Electrophysiology Service, Paulista School of Medicine, UNIFESP, Sao Paulo 04024-002, Brazil 4 Department of Medicine, Cardiology Division, Arrhythmia Service, McMaster University, Population Health Research Institute, Hamilton, ON L8L 2X2, Canada
* Author to whom correspondence should be addressed.
Received: 15 March 2012 / Revised: 16 March 2012 / Accepted: 28 March 2012 / Published: 5 April 2012
(This article belongs to the Special Issue Anticoagulants)
View Full-Text   |   Download PDF [139 KB, uploaded 24 April 2012]


Atrial Fibrillation (AF) is the most common sustained arrhythmia and 1/6 strokes is attributed to AF. The cornerstone of treatment remains maintaining sinus rhythm or appropriate ventricular rate control in addition to prevention of stroke. Oral anticoagulation therapy (OAC) with vitamin K antagonists (VKAs) has been the gold standard for almost 50 years and a significant reduction in the risk of stroke in patients with AF has been demonstrated. Nonetheless, only 50% of patients with guideline recommendations for OAC treatment actually receive VKAs and half of these will discontinue therapy within 3 to 5 years with only another half achieving therapeutic ranges more than 50% of the time. The aforementioned limitations in addition with frequent blood monitoring have prompted the development of a series of new OAC therapies. The present review focuses on the current pharmacological management for stroke prevention in patients with AF based on current and emerging evidence.
Keywords: atrial fibrillation; anticoagulants; stroke; prevention atrial fibrillation; anticoagulants; stroke; prevention
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Armaganijan, L.; Patel, D.; Dietrich, C.; Morillo, C.A. Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines. Pharmaceuticals 2012, 5, 384-397.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert